A clinical study for cardioprotective effect of empagliflozin in T2DM patients with heart failure and exploring associated factors - EMPOWERMENT

Ide Tomomi0 个研究点目标入组 40 人开始时间: 2019年3月29日最近更新: 2023年10月17日

试验速览

暂无简介。

•1)Age >20 years and <85 years males and females
•2)Inadequately controlled type 2 diabetic patients HbA1c >= 6.0% and HbA1c < 10%
•3)Type 2 diabetic patients with LV ejection fraction > 50% and a symptom of heart failure (NYHA II or III)
•4)BNP >= 35pg/dL
•5)Patients from whom a written informed consent are obtained

•1)Other than T2DM such as T1DM and secondary DM.
•2)Patients with severe infection, perioperative patients, patients with severe trauma.
•3)Patientsreceiving SGLT2 inhibitor and/or incretin-related drugs within 2 months before ingestion of study drug.
•4)Patients with idiopathic cardiomyopathy, Fabry disease, Amyloidosis cardiomyopathy.
•5)Patientswithrenal insufficiency (eGFR< 45 ml/min/1.73m2).
•6)Patients with severe respiratory disease, severe musculoskeletal conditions and unable to exercise challenge test for any other diseases, and severe anemia.
•7)Any uncontrolled endocrine disorder except type 2 diabetes.
•8)Acute coronary syndrome, stroke, or transient ischemic attack within 3 months of IC.
•9)Patient who is scheduled to undergo surgery within 3 months before IC or plan to operate within 3 months after IC.
•10)Patients who have a heart pacemaker, who have an aneurysm clip in their brain more than 20 years ago, or have a body implantationdevice(Implantedcardioverter-defibrillator ,Cochlear,otologic,or other ear implant, or Neurostimulation system).
•11)Patients with severe claustrophobia.
•12)Patients who are pregnant or breast-feeding.
•13)Patients lower than BMI 20.
•14)Patients in hyperglycemic crisis or accompanied with marked symptom of hyperglycemia and /or DKA.
•15)Patients considered inappropriate to participate in the study by the principal and/or sub- investigators.

发起方

Ide Tomomi